All In Biotech

Drug Trial Radar · NCT01553747

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,146

Actual

Start

May 29, 2012

Primary completion

Jan 9, 2014

Study completion Jan 9, 2014

Sponsor

Lead sponsor
Furiex Pharmaceuticals, IncIndustry
Sponsor type
Industry
First posted
Mar 14, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • EluxadolineDrug

    Oral tablets twice daily

  • PlaceboDrug

    Oral tablets twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency ScoresTime frame: Up to 12 weeks

Locations

253 sites in 4 countries. Site status is shown where the registry gives one.

  • Furiex Research Site

    Birmingham, Alabama

  • Furiex Research Site

    Birmingham, Alabama

  • Furiex Research Site

    Decatur, Alabama

  • Furiex Research Site

    Huntsville, Alabama

  • Furiex Research Site

    Mobile, Alabama

  • Furiex Research Site

    Montgomery, Alabama

  • Furiex Research Site

    Sheffield, Alabama

  • Furiex Research Site

    Tuscaloosa, Alabama

  • Furiex Research Site

    Glendale, Arizona

  • Furiex Research Site

    Glendale, Arizona

  • Furiex Research Site

    Mesa, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Phoenix, Arizona

  • Furiex Research Site

    Tucson, Arizona

  • Furiex Research Site

    Tucson, Arizona

  • Furiex Research Site

    Jonesboro, Arkansas

  • Furiex Research Site

    Little Rock, Arkansas

  • Furiex Research Site

    Sherwood, Arkansas

  • Furiex Research Site

    Anaheim, California

  • Furiex Research Site

    Chula Vista, California

  • Furiex Research Site

    Encinitas, California

  • Furiex Research Site

    Garden Grove, California

  • Furiex Research Site

    Huntington Beach, California

  • Furiex Research Site

    Irvine, California

  • Furiex Research Site

    La Mesa, California

  • Furiex Research Site

    La Mirada, California

  • Furiex Research Site

    Laguna Hills, California

  • Furiex Research Site

    Lakewood, California

  • Furiex Research Site

    Lincoln, California

  • Furiex Research Site

    Loma Linda, California

  • Furiex Research Site

    Lomita, California

  • Furiex Research Site

    Long Beach, California

  • Furiex Research Site

    Los Angeles, California

  • Furiex Research Site

    Newport Beach, California

  • Furiex Research Site

    North Hollywood, California

  • Furiex Research Site

    Northridge, California

  • Furiex Research Site

    Pasadena, California

  • Furiex Research Site

    Sacramento, California

  • Furiex Research Site

    San Diego, California

  • Furiex Research Site

    San Diego, California

Showing 40 of 253 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.